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ABSTRACT
Sessile serrated adenomas/polyps (SSA/Ps) are the putative precursors of the ~20% of colon
cancers with the CpG island methylator phenotype (CIMP). To investigate the epigenetic pheno-
type of these precancers, we prospectively collected fresh-tissue samples of 17 SSA/Ps and 15
conventional adenomas (cADNs), each with a matched sample of normal mucosa. Their DNA was
subjected to bisulfite next-generation sequencing to assess methylation levels at ~2.7 million
CpGs located predominantly in gene regulatory regions and spanning 80.5Mb; RNA was
sequenced to define the samples’ transcriptomes. Compared with normal mucosa, SSA/Ps and
cADNs exhibited markedly remodeled methylomes. In cADNs, hypomethylated regions were far
more numerous (18,417 vs 4288 in SSA/Ps) and rarely affected CpG islands/shores. SSA/Ps seemed
to have escaped this wave of demethylation. Cytosine hypermethylation in SSA/Ps was more
pervasive (hypermethylated regions: 22,147 vs 15,965 in cADNs; hypermethylated genes: 4938 vs
3443 in cADNs) and more extensive (region for region), and it occurred mainly within CpG islands
and shores. Given its resemblance to the CIMP typical of SSA/Ps' putative descendant colon
cancers, we refer to the SSA/P methylation phenotype as proto-CIMP. Verification studies of six
hypermethylated regions in an independent series of precancers demonstrated DNA methylation
markers’ high potential for predicting the diagnosis of SSA/Ps and cADNs. Surprisingly, proto-CIMP
in SSA/Ps was associated with upregulated gene expression; downregulation was more common
in cADNs. In conclusion, the epigenetic landscape of SSA/Ps differs markedly from that of cADNs.
These differences are a potentially rich source of novel tissue-based and noninvasive biomarkers.
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Introduction
The serrated pathway of tumorigenesis appears to
give rise to approximately one out of five sporadic
colon cancers - more specifically, those with the CpG
island methylator phenotype (CIMP) [1–6]. First
described in 1999 by Toyota et al. [7], the CIMP
hallmark is a remarkably high level of age-
independent cytosine methylation involving CpG
dinucleotide clusters (i.e., CpG islands), which are
generally unmethylated in normal somatic cells [8].
Abnormal methylation of these residues is one of the
epigenetic changes associated with gene silencing
and it has been reported in virtually all types of
human cancer [9–12]. In CIMP colon cancers,
however, this aberrant methylation occurs much
more frequently [3] and is therefore more likely to
involve CpG islands within the promoters of genes
with functional relevance for tumorigenesis. The
DNA mismatch repair (MMR) gene MLH1, for
instance, is silenced in ~55% of CIMP colon cancers
[2], and its loss results in a hypermutated, microsa-
tellite-unstable phenotype [13–16] that impacts both
the prognosis of the disease and its sensitivity to
chemotherapeutics [2,17,18].
At the precancerous level, the World Health
Organization (WHO) currently recognizes three
classes of serrated colorectal lesions: hyperplastic
polyps, traditional serrated adenomas (TSAs), and
sessile serrated adenomas/polyps (SSA/Ps) [19].
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The latter two are both thought to have malignant
potential, but SSA/Ps are considered the most
likely precursors of CIMP colon malignancies.
Like CIMP cancers, large SSA/Ps develop mainly
in the proximal colon and frequently express the
constitutively activated BRAFV600E serine/threo-
nine kinase [6,15,20,21]. The hyperactive MAPK
signaling caused by this mutant protein is thought
to be responsible for many features of the serrated
colorectal tumors, including the CIMP [22–25].
Early endoscopic removal of advanced precan-
cerous lesions has proved to be the most effective
way to reduce colon cancer-related mortality, and
large proximal-colon SSA/Ps are now considered
no less dangerous in this sense than cADNs, which
are the most frequent colon cancer precursors
[26]. However, SSA/Ps are easier to miss during
endoscopy, partly because of their location but
also because of their morphology [21,27–29].
They are nearly always flat or sessile lesions with
poorly defined borders and colors resembling
those of the normal mucosa, features that impede
both their detection and complete endoscopic
resection [30]. Finally, pathologic diagnosis of ser-
rated lesions is still subject to substantial inter-
examiner variability, so endoscopically resected
SSA/Ps are likely to be misclassified [6,21,29,31].
These factors converge to create an obvious gap in
colorectal cancer prevention, reflected by the sig-
nificant over-representation of the CIMP and
proximal-colon locations among interval cancers
(i.e., those diagnosed within 2 years of a negative
colonoscopy) [32].
Closure of this gap could be hastened by the
identification of robust sets of molecular SSA/P
biomarkers: stool-based diagnostic panels for use
in noninvasive pre-colonoscopy screening pro-
grams, and tissue-based panels for more reliable
diagnosis of these lesions in pathology labora-
tories. DNA methylation changes offer several
advantages for use as pre-colonoscopy screening
markers. Not only are they the most stable of
known epigenetic marks [33,34], they also occur
early in tumorigenesis [9–11,35–38]. Furthermore,
differentially methylated regions of the genome far
outnumber gene mutations in precancerous colon
tumors, and they tend to be found across most
lesions (unlike mutations, which are likely to be
tumor subset-specific [39–41]).
These considerations prompted us to quantita-
tively characterize genome-wide DNA hypermethy-
lation in a prospectively collected series of SSA/Ps,
each with a paired sample of normal mucosa, and to
see how the epigenetic phenotype of SSA/Ps com-
pares with those of cADNs and of CIMP colon
cancers themselves. Our primary aim was to identify
strong DNA methylation-based biomarker candi-
dates with the potential for improving the identifica-
tion and differential diagnosis of precancerous
colorectal lesions. Our secondary aim was to deter-
mine the extent to which changes in the precancers'
methylome are reflected in their gene expression
profile. To this end, we subjected the same tissue
series to RNA-sequencing analysis, which also
allowed us to identify numerous lesion-specific tran-
scriptional dysregulations with potential for devel-
opment as histopathologic biomarkers.
Results
A total of 64 fresh colon tissue samples – 17
histologically classified as SSA/Ps and 15 consid-
ered cADNs (Table 1), each with matched samples
of normal mucosa – were subjected to both gen-
ome-wide bisulfite sequencing and RNA sequen-
cing. The BRAFV600E mutation was found in 15
(88%) of the SSA/Ps and none of the cADNs.
KRAS mutations were present in BRAF-wildtype
SSA/Ps and in 6 (40%) of the 15 cADNs. As
expected for early-stage serrated tumors, none of
the SSA/Ps exhibited immunohistochemical evi-
dence of MLH1 silencing.
Proto-CIMP SSA/Ps
Figure 1(a) shows the results of unsupervised, multi-
dimensional scaling (MDS) analysis of the DNA
methylomes of the fresh-tissue series, as determined
by genome-wide bisulfite sequencing. For comparison
purposes, we used the same method to re-analyze
DNA samples from 6 proximal-colon cancers (and
matched normal mucosa samples) collected in
a previous study [42] (Supplementary Table 1). The
methylation data neatly segregated all neoplastic tis-
sues from their paired normal controls (dimension 1)
and SSA/P from cADN samples (dimension 2), and
the CIMP(+) and CIMP(-) cancers (i.e., the former
corresponding to the CIMP-high cancers described by
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Table 1. Characteristics of the prospectively collected precancerous lesions.
Patient
number Sex Age
Colon
segment
involved
Maximum
lesion
diameter
Paris
classification
#
Pit pattern
classification
†
Microscopic
appearance
Dysplasia
Δ
No. of
lesions at
study
colonoscopy
§ BRAF KRAS
S1 F 88 C 15 0-IIa IIIs SSA/P none 2 c.1799T > A
(V600E)
WT
S2 F 68 A 12 0-Is IIIs, IIIL SSA/P none 1 c.1799T > A
(V600E)
WT
S3 F 61 A 20 0-IIa II SSA/P dysplasia 4 c.1799T > A
(V600E)
WT
S4 F 71 A 15 0-IIa + IIc IV, V SSA/P dysplasia 1 c.1799T > A
(V600E)
WT
S5 M 52 C 30 0-IIa IV SSA/P none 1 c.1799T > A
(V600E)
WT
S6 F 76 C 25 0-IIa IV SSA/P * dysplasia 2 c.1799T > A
(V600E)
WT
S7 F 59 A 14 0-IIa nr SSA/P dysplasia 2 c.1799T > A
(V600E)
WT
S8 M 63 A 14 0-Is II SSA/P none 6 c.1799T > A
(V600E)
WT
S9 F 69 A 20 0-IIa II SSA/P none 1 c.1799T > A
(V600E)
WT
S10 F 45 A 25 0-Is Is SSA/P none 1 c.1799T > A
(V600E)
WT
S11 M 57 C 14 0-IIa IIIs, IIIL SSA/P none 2 WT c.37G > C (G13R)
S12 M 49 A 10 0-IIa nr SSA/P none 3 c.1799T > A
(V600E)
WT
S13 M 63 A 15 0-Is nr SSA/P none 3 c.1799T > A
(V600E)
WT
S14º F 65 A 15 0-IIa IIIs SSA/P none 14 c.1799T > A
(V600E)
WT
S15 F 36 A 15 0-IIa nr SSA/P none 2 c.1799T > A
(V600E)
WT
S16 M 55 C 25 0-IIa + Is IIIL, IV SSA/P * dysplasia 0 WT c.35G > A (G12D)
S17 F 53 C 15 0-IIa IIIs SSA/P none 1 c.1799T > A
(V600E)
WT
A1 M 58 A 25 0-IIa IV TA LGD 1 WT c.38G > T (G13V)
A2 M 68 A 35 0-Ips IV TVA LGD 1 WT c.37G > T (G13C)
A3 F 78 A 15 0-Is IV TA LGD 1 WT WT
A4 F 64 A 30 0-IIa + Is IV TA LGD 1 WT c.34G > T (G12C)
A5 F 59 A 25 0-IIa IIIL TA LGD 1 WT WT
A6 F 73 A 10 0-Is IIIs TA LGD 12 WT WT
A7 F 64 C 20 0-Is IIIL TA LGD 1 WT WT
A8 M 70 A 10 0-IIa II, IIIs TA LGD 3 WT WT
A9 F 73 A 30 0-IIa IIIL TA LGD 1 WT c.35G > T (G12V)
A10 M 77 C 40 0-Is IIIL, IV TA LGD 9 WT WT
A11 F 84 A 40 0-IIa IIIL, IV TA LGD 5 WT c.35G > T (G12V)
A12 M 61 A 25 0-Ips IIIL, IV TVA LGD 1 WT WT
A13 M 83 A 18 0-Is IIIL TA LGD 1 WT WT
A14 F 78 A 15 0-Is IIIs TA LGD 2 WT WT
A15 M 75 C 20 0-IIa + Is IV TA LGD 1 WT c.37G > T (G13C)
Abbreviations: M, male; F, female; C, cecum; A, ascending colon; TA, tubular adenoma; TVA, tubulovillous adenoma; SSA/P, sessile serrated
adenoma/polyp; LGD, low-grade dysplasia; nr: not reported.
# Macroscopic appearance of neoplastic lesions was classified according to Paris Endoscopic Classification (Endoscopy 2005; 37:570)
† Morphological analysis of colon crypt patterns according to the Kudo classification (Kudo S et al. Pit pattern in colorectal neoplasia: endoscopic
magnifying view. Endoscopy 2001; 33:367).
Δ Low-grade versus high-grade dysplasia as defined by the WHO classification of tumors (Bosman FT et al. WHO classification of tumors of the
digestive system: WHO Press, 2010).
§ Numbers include lesions analyzed in our study.
º There is only RNA sequencing data available for this sample.
* Lesions showing histological features of both SSA/Ps and cADNs. In S6, the serrated and adenomatous areas were distinct. S16 was likely a ‘serrated
tubulovillous adenoma’, as described by Bettington M et al. (Histopathology 2016, 68:578).
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Figure 1. Differentially methylated cytosines (DMCs) in precancerous and cancerous colon lesions. a. MDS plot (Supplementary
Experimental Procedures) of DNA methylation levels in SSA/Ps (n = 16); cADNs (n = 15); CIMP(+) cancers (n = 3); CIMP(-) cancers (n = 3); and
matched samples of normal mucosa for each lesion. b. Volcano plots showing the magnitude (x axis) and statistical significance (y axis) of the
differential methylation observed at DMCs identified in SSA/Ps and cADNs. X-axis: Themagnitude of differential methylation was calculated as
theM:T ratio (no. methylated reads/total no. reads) for the tumor sampleminusM:T ratio for matched normal-tissue control. Black dots: DMCs
with absolute methylation differences of <0.1 and P-values > 0.01. Yellow and blue dots: highly significant (P-value < 0.01) DMCs
(hypermethylated and hypomethylated, respectively). c. Density plot showing variance at the hypermethylated (top) and hypomethylated
(bottom) DMCs (yellow and blue dots of panel B, respectively). d. UpSet plots showing hypermethylated (left) and hypomethylated (right)
DMC sets in SSA/Ps and cADNs and their overlaps. Exact numbers of lesion-specific (•) and shared (•-•) DMCs appear above the bars. e. Overlaid
density plots showing the distributions of hypo- and hypermethylated DMCs in SSA/Ps and cADNs (left), and CIMP(+) and CIMP(-) cancers
(right). X-axis as described in panel B.
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Hinoue et al [3]., the latter to those investigators’ non-
CIMP cancers) clustered with the SSA/Ps and cADNs,
respectively.
Cytosines displaying differential methylation in
the precancerous lesions relative to their counter-
parts in matched normal tissues (DMCs) abounded
in both SSA/Ps (n = 262,503) and cADNs (n
= 302,113). Hypomethylated DMCs were much
more frequent in cADNs, while hypermethylated
DMCs were more common in SSA/Ps (Figure 1(b,
d)). The lower P-values for the hypermethylated
DMCs in SSA/Ps probably reflect the more uniform
hypermethylation levels seen across these lesions
(Figure 1(c)). Forty percent of the hypermethylated
DMCs in SSA/Ps were unique to these precancers,
while 87% of those in cADNs were also present in
SSA/Ps (Figure 1(d)). Consistent with findings
shown in Figure 1(a), the CIMP(+) cancers also
displayed more hypermethylation and less hypo-
methylation than their CIMP(-) counterparts,
although both types of differential methylation
were more striking in the cancer methylomes than
in those of the precursors (Figure 1(e)), a pattern that
reflects the increasing divergence of the lesions’
methylation profiles as they move progressively
along the two different tumorigenic pathways.
As for differentially methylated regions (DMRs)
(regions containing at least three consecutive DMCs
with directionally identical methylation changes,
separated from one another by ≤50 bp), those that
were hypermethylated were, as expected, more
numerous in SSA/Ps, while hypomethylated DMRs
were much more common in cADNs (Figure 2(a)).
Most hypermethylated DMRs were detected in both
types of precancers, but a substantial number were
SSA/P-specific (Figure 2(b)). By contrast, hypo-
methylated regions tended to be cADN-specific
(Figure 2(b)). Hypomethylation was also more likely
to be found outside CpG-rich areas and within
introns and intergenic regions (Figure 2(c)). In
both cancer precursor classes, hypermethylated
DMRs were located prevalently in CpG islands/
shores and gene promoters.
Next, to investigate the extension of this hyper-
methylation, we analyzed all of the CpG islands and
the peri-transcription start site (peri-TSS) windows
(consisting of the 2000-bp upstream and the 2000-bp
downstream from the TSS) that contained at least one
hypermethylated DMC in SSA/Ps, in cADNs, or in
both. Interestingly, in both genomic areas, hyper-
methylated DMCs were more numerous in SSA/Ps
than in cADNs (Figure 2(d) and the example in
Supplementary Figure 1). Furthermore, some SSA/
P-specific DMRs displaying relatively mild hyper-
methylation seemed to correspond to longer, more
intensely methylated regions seen in CIMP(+) colon
cancers (e.g., the large CpG island shared by the bidir-
ectional promoters of the MLH1 and EPM2AIP1
genes). As shown in Supplementary Figure 2A, aber-
rant methylation of this island involves both the
EPM2AIP1 and MLH1 promoters in CIMP(+) can-
cers, where the MLH1 expression loss triggers MMR
deficiency. In SSA/Ps, the hypermethylation is instead
confined to the EPM2AIP1 promoter and associated
with a decrease in the expression of this gene
(Supplementary Figure 2B and C).While methylation
at this locus has been investigated in cell lines [43],
tissue-based data are lacking on the specific region
where the serrated tumor-associated hypermethyla-
tion appears to begin.
As shown in Figure 2(e), genes whose peri-TSS
window included at least one hypermethylated
DMR were appreciably more common in SSA/Ps
than cADNs. (Affiliation of DMRs to genes is
described in Supplementary Experimental
Procedures; the genes themselves are listed in
Supplementary Table 2.)
Collectively, the data presented above indicate
that distinctive methylome features of CIMP(+)
colon cancers are readily detectable in their putative
precursors, SSA/Ps (albeit in less marked forms).
Therefore, this early-stage hypermethylator pheno-
type will be referred to hereafter as proto-CIMP.
Targeted verification of DMR-based biomarker
candidates for identifying colon-cancer
precursors
To explore their potential as DNA-based diagnos-
tic markers, we performed targeted verification
studies on 6 of the hypermethylated DMRs listed
in Supplementary Table 2 (3 that were SSA/
P-specific and 3 others shared by SSA/Ps and
cADNs). The selection was subjective and based
on visual inspection of the methylation patterns
across all samples in the Integrative Genomics
Viewer (IGV). Factors considered included pattern
variation across tumor samples and baseline
1092 H. R. PARKER ET AL.
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Figure 2. Differentially methylated regions (DMRs) in precursor lesions and proto-CIMP in SSA/Ps. a. Volcano plots showing
the median differential methylation (x-axis) and its statistical significance (y-axis) for DMRs found in SSA/Ps and cADNs. (See Figure
1B legend for cutoffs and color codes) b. UpSet plots showing the lesion-specificity of hypermethylated and hypomethylated DMRs
found in precancerous tumors. Exact numbers of lesion-specific (•) and shared (•-•) DMRs appear above the bars. c. Genomic location
of DMRs in SSA/Ps vs cADNs. d. Scatterplots showing the extent of methylation at regions hypermethylated in both SSA/Ps and
cADNs, and located within CpG islands (dots in the left panel) or 4-kb peri-TSS windows, i.e., TSS plus 2000-bp upstream and
downstream flanking regions (dots in the right panel). In addition, CpG islands or peri-TSS windows with at least one hypermethy-
lated CpG in either SSA/Ps or cADNs are included in the two graphics (i.e., dots along the y or x axis, respectively). e. Venn diagrams
showing overlap between sets of genes in SSA/Ps and cADNs whose peri-TSS window contained at least one hypermethylated DMR.
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methylation levels in paired normal mucosa sam-
ples. The hypermethylation patterns in our
freshly-collected tissue samples of the 6 biomarker
candidates and those of other DMRs currently
utilized as colon-cancer markers in clinical
research [3,15] are shown in Supplementary
Figure 3.
Bisulfite pyrosequencing assays were developed
to verify our biomarker candidates in the indepen-
dent series of FFPE samples (Supplementary Table
3). The results (Figure 3(a,b)) fully confirmed gen-
ome-wide bisulfite DNA sequencing data on sin-
gle-CpG methylation levels within each DMR
candidate. The 6-marker panel distinguished pre-
cancerous lesions from normal mucosa and SSA/
Ps from cADNs (Figure 3(c)) with 96.7% accuracy
(Supplementary Figure 4A). Preliminary data on
FFPE samples of TSAs (four KRAS-mutant, one
KRAS/BRAF wild-type) and colon cancers ana-
lyzed with this panel (Supplementary Figure 4B)
suggest that the KRAS-mutant TSA methylome
more closely resembles that of cADNs than that
of SSA/Ps and confirm findings shown in Figure 1
(a), whereby colon cancer clustering with SSA/Ps
or cADNs appears to be CIMP status-dependent.
The SSA/P and cADN transcriptomes
To explore how the methylome profiles reported
above are reflected in the transcriptomes of pre-
cancerous colon lesions, we performed RNA
sequencing-based gene expression analyses on the
64 fresh-tissue samples used for methylation pro-
filing. The results readily segregated most precan-
cers into SSA/Ps and cADNs (Figure 4(a,b)).
MetaCore enrichment analysis of the most strik-
ingly dysregulated genes in the precancers (Figure
4(c) and Supplementary Table 4) identified path-
ways involved in ‘Cell adhesion_extracellular
remodelling’ and ‘Development_WNT signaling’
as the ones most markedly altered in SSA/Ps and
cADNs, respectively.
As shown in Figure 4(c), the major gene expres-
sion alterations in cADNs were usually downregu-
lations, whereas increased expression was more
common in SSA/Ps. The predominance of upre-
gulated transcription in lesions displaying proto-
CIMP illustrates the emerging complexities of
DNA methylation’s relation to transcription.
Although hypermethylation of promoter CpG
islands is frequently cited as a silencing epigenetic
mark [44], the relation between peri-TSS methyla-
tion and gene expression levels in our samples
varied widely. For example, as shown in Figure 4
(d), substantial hypermethylation was associated
with significantly upregulated expression of ZIC2
and ZIC5 but mildly reduced expression of HUNK.
Inverse (hypermethylation with downregulation,
hypomethylation with upregulation) and positive
(hypermethylation with upregulation, hypomethy-
lation with downregulation) relations were
encountered with similar frequencies.
Furthermore, significantly dysregulated expression
was also observed for many genes which – unlike
those represented in Figure 4(d) – had no evidence
of aberrant promoter methylation. Figure 4(e)
(and Supplementary Figures 5 and 6) provide
more details on the relations between gene expres-
sion and DNA methylation at the ZIC2, ZIC5, and
HUNK loci. In situ hybridization-based tissue
staining patterns for ZIC2 and HUNK mRNAs in
precancerous lesions are shown in Figure 5.
Discussion
Previous studies have analyzed DNA methylation
alterations in colon cancers with an eye to their
exploitation as diagnostic markers. In 2006,
Weisenberger et al. analyzed methylation at 195
genetic loci and identified a panel of 5 DMRs that
discriminated between CIMP and non-CIMP
colon cancers [15]. This panel was refined by the
same group based on the analysis of ~27,000 CpG
sites [3]. Although several groups have also used
these panels (and other previously-identified sets
of cancer-associated methylation markers [7]) to
classify precancerous colon lesions [14,20,45–53],
their diagnostic potential in this setting is uncer-
tain. While some regions might be aberrantly
methylated from the outset of colon tumorigen-
esis, other DMRs could conceivably be present in
cancers but absent or poorly developed in early-
stage colon tumors (e.g., that affecting the MLH1
promoter).
Dehghanizadeh et al. recently attempted to
explore this uncharted territory using a microarray-
based assay to assess methylation at ~450,000 CpG
sites [41]. However, the series of precancerous
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Figure 3. Bisulfite pyrosequencing verification of 6 hypermethylated DMRs. Methylation levels at each CpG site of (a) 3 SSA/
P-specific DMRs and (b) 3 DMRs shared between SSA/Ps and cADNs. Verification assay results in 61 FFPE colon tissue samples (left)
are compared with those of genome-wide bisulfite sequencing of the fresh tissue series (right). DMR-containing loci (red box) and
CpG islands (blue horizontal bars) are schematically represented below graph pairs. c. Hierarchical clustering heatmap of the 61 FFPE
tissue samples based on the mean methylation level across all CpGs in each DMR. The cADN cluster contains two subgroups,
probably reflecting their different frequencies of KRAS mutations. The SSA/P cluster also contains a subgroup of lesions with higher
levels of methylation at all 6 markers, presumably reflecting these patients’ significantly older age when the lesions were discovered
(mean: 66.3 years versus 54.5 years in the subgroup with lower methylation levels; P = 0.01). Significant differences between
subgroups regarding other clinical variables (Supplementary Table 3) were not observed.
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Figure 4. Analysis of the SSA/P and cADN transcriptomes in light of the lesions’ methylome profiles. (a) MDS plot and (b) hierarchical
clustering heatmap of the 17 SSA/Ps and 15 cADNs and their normal mucosal samples. Asterisks indicate the two samples with intermediate
profiles (for details, see Table 1). Hierarchical clustering in B was based on expression levels of the 10,000 genes with most highly variable
expression. c. Venn diagrams showing the precursor-lesion specificity of the most dysregulated genes (P-value < 10−10 and log2 fold
change > 1). d. Scatter plots showing the variable relation between themagnitude of differential DNAmethylation (x axis) and the expression
(y axis) for SSA/Ps (vs matched normal mucosa samples). Genes with at least one DMR (P-value < 0.05) in their peri-TSS windows and
dysregulated expression (P-value < 0.05) are shown. Red dots: subsets of genes with a median methylation difference of ≥ 0.1 and log2 fold
change in expression of >1. ZIC2, ZIC5, andHUNK are highlighted to illustrate the heterogeneous relation between DNAmethylation and gene
expression. e. Methylation levels (top) and gene expression (bottom) data for the ZIC2, ZIC5, and HUNK loci in SSA/Ps (pink), cADNs (blue), and
corresponding samples of normal mucosa (light-pink and light blue, respectively). Areas outlined in black are those displaying differential
methylation (see details in Supplementary Figures 5 and 6).
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lesions they studied included only 5 SSA/Ps (archi-
val samples: fresh or FFPE) and 3 cADNs (all from
patients with familial polyposis), and, with the
exception of one of the SSA/Ps, none of the pre-
cancerous lesions were accompanied by a paired
sample of normal mucosa. Our methylation analy-
sis included a total of 64 prospectively collected,
fresh-tissue samples representing the two major
classes of sporadic precancerous colon lesions,
SSA/Ps and cADNs, and patient-matched samples
of non-neoplastic tissues. The results show that
DMR profiles can distinguish colon cancer precur-
sors from normal colon tissues, and they can also
differentiate between the SSA/Ps and cADNs.
Hypermethylation within gene regulatory regions –
a common feature of tumorigenesis in general –was
encountered frequently in both types of precancers.
However, in SSA/Ps it is appreciably more
Figure 5. In situ hybridization analysis of ZIC2, HUNK, and ANXA10 mRNAs in SSA/Ps and cADNs. ZIC2 expression (red
punctate labeling) is (a) present in SSA/Ps and (b) absent in cADNs. HUNK (brown punctate labeling) is (c) almost absent in SSA/Ps
(very low-level expression was present at the bottom of serrated crypts, see inset) and (d) expressed in cADNs. Control staining for
ANXA10, a known SSA/P-specific marker[25,73–75] was (e) strongly positive in SSA/Ps (dense red punctate labeling) and (f) absent in
cADNs.
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pervasive, and it shares many features (albeit in
milder forms) with the hypermethylation typical
of the CIMP(+) colon cancers believed to develop
from SSA/Ps – hence our referral to the SSA/P
phenotype as proto-CIMP (a generally descriptive
term that highlights the progressive nature of the
biological process underlying the phenotype, not
intended for clinical use in the classification of
precancerous colorectal lesions). Global hypo-
methylation of the genome is also a common fea-
ture of tumorigenesis, and it was clearly evident in
both cADNs and CIMP(-) colon cancers. It has also
been reported in a single SSA/P investigated with
whole-genome bisulfite sequencing [41]. However,
our data indicate that SSA/Ps and CIMP(+) cancers
are generally spared from the wave of demethyla-
tion that occurs during conventional colorectal
tumorigenesis (at least within the 80.5 Mb area of
the genome we investigated). This epigenetic phe-
notype might thus be a novel feature of CIMP
tumorigenesis. As such, it clearly deserves further
investigation with a whole-genome study of methy-
lation in several precursor lesions of different types.
The six markers verified in this study (LOX, LEF1-
AS1, SFRP4, ZNF793, SYT9, and LINC00693) dis-
played high accuracy (97%) in distinguishing the
colon precancers from normal mucosa and also in
differentiating between the two main classes of pre-
cancerous tumors. However, the long list of DMRs
we identified (Supplementary Table 2) should be
scrupulously mined to find additional markers,
which can be used to develop a precolonoscopic
stool-DNA test that excels in both sensitivity (i.e.,
detection of precancerous as well as cancerous
lesions) and specificity (i.e., differentiation of SSA/
Ps/CIMP(+) cancers and cADNs/CIMP(-) cancers).
Indeed, the vast majority of DMRs we identified in
the precancers, including the 6 markers, appear to
undergo little or no negative selection during trans-
formation and therefore were also present in colon
cancers. Recently, a stool-DNA test, whose targets
include aberrant BMP3 and NDRG4 methylation,
has produced promising results in the pre-
colonoscopy detection of cancers and advanced pre-
cancerous lesions of the colon (including advanced
SSA/Ps) [54]. As shown in Supplementary Figure 3Q
and R, these markers, which were also in our list,
performed well in the identification of our CIMP(+)
and proto-CIMP tumors.
The results of our RNA sequencing studies con-
firm the increasing body of evidence highlighting
the complex relation between DNA methylation
and gene expression [44]. Emphasis in the litera-
ture has frequently been placed on the association
between gene silencing and hypermethylation of
promoter CpG islands, since the latter is an estab-
lished mechanism underlying cancer-related inac-
tivation of tumor suppressor genes (e.g., MLH1 in
colon tumorigenesis) [43,55,56]. Analysis of our
data failed to reveal any genes with established
tumor-suppressor functions among those with
downregulated expression and peri-TSS hyper-
methylation in precancerous lesions. HUNK, for
example, encodes a protein kinase that appears to
negatively regulate normal intestinal cell prolifera-
tion [57], but it also seems to promote mammary
tumorigenesis [58]. As for its methylation pattern,
a substantial portion of HUNK’s peri-TSS window
was hypermethylated in the CIMP(+) cancers. In
contrast, the methylation observed in SSA/Ps was
reduced in level and confined to a shorter stretch
of CpG sites. (The latter feature recalls the aber-
rant methylation involving the CpG island shared
by the EPM2AIP1 and MLH1 promoters, which
affected the MMR gene promoter only in the more
advanced stages of tumorigenesis.) The methyla-
tion present in the SSA/Ps was nonetheless asso-
ciated with mildly reduced HUNK expression
(Figure 4(e) and Supplementary Figure 5A).
Interestingly, HUNK methylation (even milder
than that seen in SSA/Ps) was also identified in
some cADNs, where it was associated with upre-
gulated expression of the gene (Supplementary
Figure 5B).
Consistent with previous reports [3,59], the
CpG island hypermethylation events we detected
mainly affected the promoter regions of genes
displaying little or no expression in precancerous
and normal mucosa. Some of these genes are
known to be marked during embryonic develop-
ment by polycomb repressive complex 2 (PRC2),
which mediates H3K27 trimethylation, a hallmark
of gene silencing. During tumorigenesis, these loci
display increases in DNA methylation together
with decreases in H3K27me3. The mechanisms
responsible for these changes are incompletely
understood [60–64], but they are believed by
some to tighten repression of the target gene’s
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expression, rendering it more difficult to
induce [65].
Notably, however, the markedly dysregulated
gene expression in our SSA/Ps tended to involve
upregulation rather than downregulation (Figure 4
(c)), despite the lesions’ proto-CIMP. Indeed, sev-
eral upregulated genes exhibited hypermethylation
in their proximal regulatory regions (Figure 4(d)).
For example, the ZIC2/ZIC5 locus (Figure 4 and
details in Supplementary Figure 6) was methylated
strongly and extensively in SSA/Ps – and less so in
cADNs – and yet, the expression of these two
genes was re-activated only in the SSA/Ps (after
PRC2 repression during embryonic development).
Additional work is needed to unravel the ties
between DNA methylation and gene expression
at this locus (and others) in SSA/Ps and cADNs.
The fairly small differences in the two lesions’
hypermethylation patterns might well be asso-
ciated with more marked differences at the chro-
matin level.
Gene expression is also modulated by cis epige-
netic signals other than DNA methylation, includ-
ing myriad histone modifications, and by long-
range regulatory signals, such as those classically
involving enhancers via CTCF-mediated chroma-
tin loop formation [66]. And, naturally, differential
transcription-factor expression in the two types of
lesions (e.g., the SSA/P-specific re-expression of
ZIC2 and ZIC5, whose roles in tumorigenesis are
completely unknown) will be reflected in these
proteins’ differential binding patterns in gene reg-
ulatory regions. The temporal coordination of
these factors is highly complex and involves sub-
stantial backward regulation. For example, the
binding affinity of many transcription factors –
and CTCF – varies with the methylation status of
their binding sites and, contrary to common belief,
many factors preferentially bind methylated DNA
[67–70]. Altered DNA methylation patterns in
SSA/Ps and cADNs thus create different platforms
for recruiting DNA – and chromatin-binding pro-
teins, leading to changes in gene expression pat-
terns, such as alternative promoter usage [71,72]
Regardless of their functional relations with our
DNA methylation data, the transcriptome differ-
ences we documented between SSA/Ps and cADNs
can also be fruitfully exploited to develop tissue
staining assays to differentiate these lesions with
confidence. The extensive list of genes in
Supplementary Table 4 represents a rich source
of promising candidate markers that can be used
for this purpose. For tissue staining, the recently
developed in situ hybridization method we
employed is straightforward and produces highly
sensitive and specific results. It is a valuable alter-
native when specific antibodies are unavailable or
do not perform well in immunohistochemistry,
and excellent for tissue staining of non-coding
RNAs.
Our list of potential expression-based SSA/P
markers shows overlap with those identified by
other groups (e.g., ANXA10, which is reportedly
a highly specific marker of serrated-pathway
colon tumors [25,73–75]). Indeed, our transcrip-
tomic data appreciably extend previously pub-
lished microarray findings [76–78] and are
similar to RNA sequencing-based results from
another group [74,79] (Supplementary Figure
7A). However, separate signatures are also needed
for other types of serrated lesions and lesions
typically found outside the proximal colon
(hyperplastic polyps in particular, which are
encountered very frequently). These areas are
already being explored in several studies
[73,79,80], including the previously mentioned
study based on RNA sequencing, which showed
that SSA/Ps can be differentiated from hyperplas-
tic polyps based on transcriptome profiles
(Supplementary Figure 7B) [79].
In conclusion, our study represents the most
comprehensive genome-wide comparison of
DNA methylation and gene expression in SSA/
Ps and cADNs. The 6 verified markers in this
study could be supplemented with other promis-
ing candidates from our DMR dataset and vali-
dated in future studies on a larger series of
precancerous lesions. As with the gene expres-
sion, the sample set should be extended to
involve all types of colonic tumors, including
those from the distal colon. The findings from
such studies will have clinical implications for
the pre-colonoscopy stool-DNA-based detec-
tion – and identification – of early-stage colon
tumors and for their more accurate molecular
histological diagnosis.
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Patients and methods
Analyses of prospectively collected tissues
Tissues
The fresh tissues used to study DNA methylation
and gene expression were prospectively collected
during colonoscopies performed between 2014
and 2017 at Cremona Hospital (Italy) or Zurich
Triemli Hospital (Switzerland). The study was
approved by both hospitals’ research ethics com-
mittees. Donors provided written consent to tissue
collection, testing, and data publication. Samples
were numerically coded to protect donors’ rights
to confidentiality and privacy. Precancerous lesions
were collected from the cecum or ascending colon
during colonoscopies that were negative for cancers
(Table 1). Each lesion was accompanied by
a control sample of normal mucosa located >2 cm
from the tumor (essential if baseline differences
between tissue donors are to be accounted for).
Lesions analyzed had: 1) maximum diameters of
≥10 mm (to ensure that sufficient tissue was left
for the histological examination) and 2) Paris class
Is or IIa morphologic features (i.e., sessile polyps
and nonpolypoid lesions that were slightly elevated
above the surrounding mucosa) [81] to increase the
likelihood of including SSA/Ps. Tissue samples
were placed in tubes filled with AllProtect Tissue
Reagent (Qiagen, Hilden, Germany), held at 4°C
overnight, and stored at −80°C prior to simulta-
neous DNA/RNA extraction with Qiagen’s
AllPrep Mini Kit. All study tissues were histologi-
cally classified according to WHO criteria [19] by
an expert gastrointestinal pathologist at the hospital
furnishing the lesion.
BRAF and KRAS mutation analysis
All sampleswere subjected to standard Sanger sequen-
cing (Supplementary Experimental Procedures) to
identify mutations in BRAF exon 15 (site of the muta-
tional hotspot that gives rise to theV600E variant) and
KRAS exon 2 (codons 12 and 13, which are frequently
mutated).
Genome-wide bisulfite DNA sequencing and RNA
sequencing
For methylation analysis, sequencing libraries
were prepared using 1 microgram of DNA per
sample, according to the Roche SeqCapEpi
CpGiant protocol (Roche, Rotkreutz,
Switzerland) (Supplementary Experimental
Procedures), and bisulfite-converted prior to
capture with a pre-designed probe pool (Roche-
NimbleGen, Madison, WI). This target-
enrichment procedure allowed us to interrogate
80.5Mb of the genome containing ~2.7 x 106
CpG sites, with thorough coverage of intra- and
intergenic CpG islands and those in gene pro-
moters, and more limited coverage of CpG
shores and CpG nucleotides in enhancers and
gene bodies. Captured libraries were sequenced
on an Illumina 2500 system (Illumina, San
Diego, CA) (125-bp paired-end reads).
RNA sequencing was restricted to samples with
total RNA integrity numbers exceeding 6.5. Poly-A
RNA was isolated from 100 ng of total RNA. PCR-
amplified cDNA sequencing libraries were pre-
pared according to the Illumina TruSeq Stranded
mRNA Library preparation protocol and
sequenced on an Illumina HiSeq 4000 system
(150-bp paired-end reads).
Analysis of methylome and transcriptome data
Bisulfite- and RNA-sequencing reads were aligned to
the GRCh37/hg19 human reference genome using
Bismark/Bowtie 2 [82] and Salmon [83], respectively.
Quality-control analysis excluded one SSA/P (S14 in
Table 1) from the methylome analysis because the
probe pool’s target capture specificity in its matched
normal mucosa sample was low. Differentially methy-
lated cytosines (DMCs) (i.e., those displaying hyper-
or hypo- methylation in tumor tissues vs. matched
normal controls) were identified using the BiSeq
R-package [84]. Differentially methylated regions
(DMRs) were defined as clusters of adjacent DMCs
that were consistently hyper- or hypomethylated.
(Data pre-processing, quality control, and BiSeq ana-
lysis are described in Supplementary Experimental
Procedures.) Genes displaying significant differential
expression in precancerous lesions (vs matched sam-
ples of normal mucosa) were identified using the
edgeR R-package [85] (details in Supplementary
Experimental Procedures).
Raw methylome and transcriptome data are
deposited in ArrayExpress (accession numbers:
E-MTAB-6952; E-MTAB-6951; E-MTAB-6949).
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FFPE tissue studies
Tissues
Fresh-tissue findings on DNA methylation were
verified in formalin-fixed, paraffin-embedded
(FFPE) colon tissues (precancerous and normal
mucosa) collected proximal to the splenic flexure.
The tissues were obtained from the Zurich
University Hospital Pathology Archives with local
ethics committee approval and written donor con-
sent (Supplementary Table 3). DNA was extracted
from samples using the truXTRAC kit (Covaris,
Woburn, MA) (Supplementary Experimental
Procedures). FFPE samples were histologically
classified and genotyped for BRAF and KRAS, as
described above for the prospectively collected tis-
sue series.
Bisulfite pyrosequencing
DNA methylation patterns at 6 selected DMRs were
verified in the independent FFPE sample series with
bisulfite pyrosequencing. DNA (500 ng per sample)
was treated with sodium bisulfite using the Zymo
Research DNA Methylation Lightning kit (Zymo
Research, Irvine, CA). The bisulfite-converted DNA
(20 ng) was amplified using biotinylated primers, and
PCR products were pyrosequenced on a PyroMark
Q24 Autoprep system (Qiagen) (Supplementary
Experimental Procedures; Supplementary Table 5).
The accuracy of the 6-marker panel in distinguishing
the two types of precancerous lesions was calculated
with a support vectormachinemodel (Supplementary
Experimental Procedures).
In-situ hybridization and immunohistochemistry
In situ-hybridization studies of representative
lesions were performed with the RNAscope 2.0
assay (Advanced Cell Diagnostics, Hayward, CA),
which uses multiple probes for each RNA and
branched DNA molecules to amplify signals
(Supplementary Experimental Procedures). MLH1
immunohistochemistry was performed on all
lesions, as previously described [56].
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